Total Assets (Quarterly) Chart

View Total Assets (Quarterly) for PLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Assets (Quarterly) Chart
Start Trial

Historical Total Assets (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 110.34M
March 31, 2026 102.34M
December 31, 2025 82.35M
September 30, 2025 82.26M
June 30, 2025 78.49M
March 31, 2025 73.89M
December 31, 2024 73.42M
September 30, 2024 61.56M
June 30, 2024 91.54M
March 31, 2024 89.82M
December 31, 2023 84.43M
September 30, 2023 87.57M
June 30, 2023 88.42M
March 31, 2023 66.56M
December 31, 2022 55.79M
September 30, 2022 56.71M
June 30, 2022 60.64M
March 31, 2022 68.39M
December 31, 2021 73.66M
September 30, 2021 83.48M
June 30, 2021 108.20M
March 31, 2021 102.79M
December 31, 2020 67.93M
September 30, 2020 72.31M
June 30, 2020 71.71M
Date Value
March 31, 2020 82.88M
December 31, 2019 45.39M
September 30, 2019 53.73M
June 30, 2019 55.24M
March 31, 2019 61.04M
December 31, 2018 61.13M
September 30, 2018 65.75M
June 30, 2018 51.72M
March 31, 2018 64.80M
December 31, 2017 72.21M
September 30, 2017 61.06M
June 30, 2017 59.00M
March 31, 2017 71.85M
December 31, 2016 82.25M
September 30, 2016 70.47M
June 30, 2016 78.86M
March 31, 2016 87.31M
December 31, 2015
September 30, 2015 59.49M
June 30, 2015 65.95M
March 31, 2015 72.05M
December 31, 2014 78.47M
September 30, 2014 84.80M
June 30, 2014 96.65M
March 31, 2014 103.42M

Total Assets Definition

Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.

Read full definition.

Total Assets (Quarterly) Range, Past 5 Years

View Total Assets (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Assets (Quarterly) Benchmarks

View Total Assets (Quarterly) Benchmarks
Start Trial
Altimmune, Inc. 527.21M
Taysha Gene Therapies, Inc. 470.43M
Humacyte, Inc. 138.09M
Agenus, Inc. 172.69M
Amgen, Inc. 95.64B

Total Assets (Quarterly) Related Metrics